News Releases

CHP Canada Statement on using NSAIDs to treat COVID-19 symptoms

Consumer Health Products Canada (CHP Canada) advises all Canadians who have questions about pain and fever management during the COVID-19 pandemic to rely on health professionals, public health officials, government-run health portals, and approved product labels.

The recent debate about a link between the use of non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and poorer COVID-19 outcomes is not based on clinical evidence, as Health Canada has now also stated. If you are taking these mediations on directions from your doctor, do not stop without consulting them first. Speak with a health professional if you are unsure about what is the best therapy for you.

With respect to how they can reduce the overall risks of the COVID-19 pandemic, we remind all Canadians to rely on the recommendations of their local public health officials or the Public Health Agency of Canada.

The World Health Organisation released this statement on Twitter on March 18th, 2020:

The Health Canada statement on this issue, as published on March 20th, 2020, can be found here.

Similar statements which were shared with citizens in the European Union, the United States, and the United Kingdom can be found below:

EU: EMA Statement

USA: CHPA Statement

United Kingdom: PAGB Statement